Subscribe
JarTee / Shutterstock.com
22 July 2025NewsAmericasMuireann Bolger

Novartis fails latest bid to block Entresto copies

Judge said it was unjustified to allow pharma giant’s exclusivity to continue indefinitely | Loss of monopoly over $7.8bn drug set to have marked revenue impact on the company.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Fed Circ refuses to stay Novartis feud with MSN over Entresto
27 May 2025   Litigation concerns Novartis’ blockbuster $6bn heart failure drug, which has already expired | Indian generic company hoped to stay proceedings to prepare appeal against unfavourable decision.
Americas
Patent cliff: 5 blockbusters running out of road
1 April 2025   MSD, Novartis and Eli Lilly are among those whose multi-billion-dollar patents are hurtling towards expiration, writes Marisa Woutersen.


Editor's picks

BMS blocks biosimilar version of blockbuster cancer drug in India
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025

Editor's picks

Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

More on this story

Americas
Fed Circ refuses to stay Novartis feud with MSN over Entresto
27 May 2025   Litigation concerns Novartis’ blockbuster $6bn heart failure drug, which has already expired | Indian generic company hoped to stay proceedings to prepare appeal against unfavourable decision.
Americas
Patent cliff: 5 blockbusters running out of road
1 April 2025   MSD, Novartis and Eli Lilly are among those whose multi-billion-dollar patents are hurtling towards expiration, writes Marisa Woutersen.

More on this story

Americas
Fed Circ refuses to stay Novartis feud with MSN over Entresto
27 May 2025   Litigation concerns Novartis’ blockbuster $6bn heart failure drug, which has already expired | Indian generic company hoped to stay proceedings to prepare appeal against unfavourable decision.
Americas
Patent cliff: 5 blockbusters running out of road
1 April 2025   MSD, Novartis and Eli Lilly are among those whose multi-billion-dollar patents are hurtling towards expiration, writes Marisa Woutersen.

More features

BMS blocks biosimilar version of blockbuster cancer drug in India
WATCH: Protecting life science innovations involving big data, AI and machine learning
AbbVie blocks Humira antitrust suit
WATCH: Enabling success—mastering s112 in the new era of life sciences patents
AstraZeneca suffers defeat over $7bn diabetes patent
US firm Brownstein nabs five from Crowell ‘at pivotal moment’
American Regent secures rare PI win in Hatch-Waxman dispute
WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US